BioCentury | Oct 10, 2019
Financial News

As IPO queue swells, BioNTech underwhelms in NASDAQ debut

Shares of BioNTech sagged 5% to $14.24 in its first day of trading Thursday after the company priced its IPO amid diminished expectations. The German biotech had hoped to obtain a valuation well above $4...
BioCentury | Sep 24, 2019
Financial News

BioNTech will do without $100M from Hong Kong-based series B investor

An updated IPO prospectus revealed that BioNTech no longer expects a $100 million contribution to its previously announced series B round from an undisclosed Hong Kong-based investor. The company's initial IPO filing on Sept. 10...
BioCentury | Sep 11, 2019
Financial News

BioNTech IPO filing says trade war, Hong Kong unrest may be delaying $100M of series B

BioNTech’s IPO filing revealed that it has not yet received $100 million from a Hong Kong-based investor who was part of its recent $325 million series B round, likely because of “disruptions” in Hong Kong...
BioCentury | Mar 27, 2019
Financial News

NASH company Genfit gains dual listing via NASDAQ offering

Liver disease company Genfit gained $1.85 to $22.17 on Wednesday after the company raised a combined $135.1 million via a NASDAQ offering and concurrent private placement. In the NASDAQ offering, Genfit S.A. (Euronext:GNFT; NASDAQ:GNFT) raised...
BioCentury | Mar 1, 2019
Financial News

Genfit files for NASDAQ listing

France’s Genfit S.A. (Euronext:GNFT) proposed a NASDAQ offering that would give the company a dual listing. The company, whose lead molecule elafibranor is in Phase III testing to treat non-alcoholic steatohepatitis (NASH), proposed to raise...
BioCentury | Feb 28, 2019
Financial News

Genfit files for NASDAQ listing

France’s Genfit S.A. (Euronext:GNFT) proposed a NASDAQ offering that would give the company a dual listing. The company, whose lead molecule elafibranor is in Phase III testing to treat non-alcoholic steatohepatitis (NASH), proposed to raise...
BioCentury | Dec 14, 2018
Financial News

Moderna raises $604M in record IPO, loses $1.4B in trading debut

Moderna Inc. (NASDAQ:MRNA) tumbled out of the gate on Dec. 7, losing $4.40 (19%) to $18.60 in its trading debut for a loss of $1.4 billion in market cap as U.S. stocks across the board...
BioCentury | Dec 7, 2018
Financial News

Moderna sets IPO record with upsized $604M offering

Brushing aside market volatility that has led several biotechs to miss their desired valuations in recent weeks, Moderna Inc. (NASDAQ:MRNA) raised $604.3 million in an upsized IPO late Thursday through the sale of 26.3 million...
BioCentury | Nov 30, 2018
Financial News

Moderna proposes terms for record IPO

Moderna Inc. (Cambridge, Mass.) proposed terms for an IPO in which it would raise about $500 million. If the mRNA company succeeds, the deal would be the largest ever on NASDAQ for a precommercial biotech....
BioCentury | Nov 28, 2018
Financial News

Moderna proposes terms for record IPO

Moderna Inc. (Cambridge, Mass.) proposed terms for an IPO in which it would raise about $500 million. If the mRNA company succeeds, the deal would be the largest ever on NASDAQ for a precommercial biotech....
Items per page:
1 - 10 of 94
BioCentury | Oct 10, 2019
Financial News

As IPO queue swells, BioNTech underwhelms in NASDAQ debut

Shares of BioNTech sagged 5% to $14.24 in its first day of trading Thursday after the company priced its IPO amid diminished expectations. The German biotech had hoped to obtain a valuation well above $4...
BioCentury | Sep 24, 2019
Financial News

BioNTech will do without $100M from Hong Kong-based series B investor

An updated IPO prospectus revealed that BioNTech no longer expects a $100 million contribution to its previously announced series B round from an undisclosed Hong Kong-based investor. The company's initial IPO filing on Sept. 10...
BioCentury | Sep 11, 2019
Financial News

BioNTech IPO filing says trade war, Hong Kong unrest may be delaying $100M of series B

BioNTech’s IPO filing revealed that it has not yet received $100 million from a Hong Kong-based investor who was part of its recent $325 million series B round, likely because of “disruptions” in Hong Kong...
BioCentury | Mar 27, 2019
Financial News

NASH company Genfit gains dual listing via NASDAQ offering

Liver disease company Genfit gained $1.85 to $22.17 on Wednesday after the company raised a combined $135.1 million via a NASDAQ offering and concurrent private placement. In the NASDAQ offering, Genfit S.A. (Euronext:GNFT; NASDAQ:GNFT) raised...
BioCentury | Mar 1, 2019
Financial News

Genfit files for NASDAQ listing

France’s Genfit S.A. (Euronext:GNFT) proposed a NASDAQ offering that would give the company a dual listing. The company, whose lead molecule elafibranor is in Phase III testing to treat non-alcoholic steatohepatitis (NASH), proposed to raise...
BioCentury | Feb 28, 2019
Financial News

Genfit files for NASDAQ listing

France’s Genfit S.A. (Euronext:GNFT) proposed a NASDAQ offering that would give the company a dual listing. The company, whose lead molecule elafibranor is in Phase III testing to treat non-alcoholic steatohepatitis (NASH), proposed to raise...
BioCentury | Dec 14, 2018
Financial News

Moderna raises $604M in record IPO, loses $1.4B in trading debut

Moderna Inc. (NASDAQ:MRNA) tumbled out of the gate on Dec. 7, losing $4.40 (19%) to $18.60 in its trading debut for a loss of $1.4 billion in market cap as U.S. stocks across the board...
BioCentury | Dec 7, 2018
Financial News

Moderna sets IPO record with upsized $604M offering

Brushing aside market volatility that has led several biotechs to miss their desired valuations in recent weeks, Moderna Inc. (NASDAQ:MRNA) raised $604.3 million in an upsized IPO late Thursday through the sale of 26.3 million...
BioCentury | Nov 30, 2018
Financial News

Moderna proposes terms for record IPO

Moderna Inc. (Cambridge, Mass.) proposed terms for an IPO in which it would raise about $500 million. If the mRNA company succeeds, the deal would be the largest ever on NASDAQ for a precommercial biotech....
BioCentury | Nov 28, 2018
Financial News

Moderna proposes terms for record IPO

Moderna Inc. (Cambridge, Mass.) proposed terms for an IPO in which it would raise about $500 million. If the mRNA company succeeds, the deal would be the largest ever on NASDAQ for a precommercial biotech....
Items per page:
1 - 10 of 94